

SPECIALTY GUIDELINE MANAGEMENT

CINQAIR (reslizumab)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Cinqair is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype.

Limitations of Use:

- Not for treatment of other eosinophilic conditions
- Not for the relief of acute bronchospasm or status asthmaticus

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review: Member's chart or medical record showing baseline blood eosinophil count (initial request only)

III. CRITERIA FOR INITIAL APPROVAL

Authorization of 6 months may be granted for treatment of asthma when all of the following criteria are met:

- A. Member is 18 years of age or older.
- B. Member has baseline blood eosinophil count of at least 400 cells per microliter.
- C. Member has inadequate asthma control (e.g., hospitalization or emergency medical care visit within the past year) despite current treatment with both of the following medications at optimized doses:
 1. Inhaled corticosteroid
 2. Additional controller (long-acting beta₂-agonist, leukotriene modifier, or sustained-release theophylline)
- D. Member will not use Cinqair as monotherapy.
- E. Member will not use Cinqair concomitantly with other biologics indicated for asthma (e.g., Dupixent, Fasenra, Nucala, Xolair).

IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for treatment of asthma when all of the following criteria are met:

- A. Member is 18 years of age or older.

Reference number(s)
1654-A

- B. Asthma control has improved on Cinqair treatment as demonstrated by a reduction in the frequency and/or severity of symptoms and exacerbations.
- C. Member will not use Cinqair as monotherapy.
- D. Member will not use Cinqair concomitantly with other biologics indicated for asthma (e.g., Dupixent, Fasenra, Nucala, Xolair).

V. OTHER

Note: If the member is a current smoker or vaper, they should be counseled on the harmful effects of smoking and vaping on pulmonary conditions and available smoking and vaping cessation options.

VI. REFERENCES

1. Cinqair [package insert]. Frazer, PA: Teva Respiratory, LLC; January 2019.
2. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet Respir Med*. 2015;3(5):355-366.
3. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2019 update. Available at: <https://ginasthma.org/reports/>. Accessed March 5, 2020.